Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

Barclays analyst Glen Santangelo has reinstated an Overweight rating on Tarsus Pharmaceuticals (NASDAQ: TARS) and set a price target of $110 for the stock. This indicates a positive outlook for the company's performance in the market.